AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9
27 May 2021 //
GLOBENEWSWIRE
AFFiRiS presents positive preclinical in vivo data with antibody mAB C6-17
27 Apr 2021 //
PHARMABIZ
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17
27 Apr 2021 //
PRESS RELEASE
AFFiRiS Announces FDA to its pre-IND Sub for Phase 2 trial with AFFITOPE PD01
27 Jan 2020 //
FINANCE YAHOO